CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.4

ph-index = 6

Forward Citations = 97(Granted Patents)

Company Filing History:

Theravance Biopharma R&d Ip, LLC

patents

Years Active: 2006-2020

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10745394 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2020-08-18),

2. 10377751 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2019-08-13),

3. 9206172 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2015-12-08),

4. 8476440 - Process for preparing an intermediate to mu opioid receptor antagonists (2013-07-02),

5. 8263618 - 8-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonists (2012-09-11),

6. 8247559 - Process for preparing an intermediate to mu opioid receptor antagonists (2012-08-21),

7. 8080565 - Substituted 4-amino-benzylpiperidine compounds (2011-12-20),

8. 7932402 - Process for preparing an intermediate to opioid receptor antagonists (2011-04-26),

9. 7772434 - [object Object] (2010-08-10),

10. 7622508 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2009-11-24),

11. 7557247 - [object Object] (2009-07-07),

12. 7368463 - Substituted 4-amino-1-benzylpiperidine compounds (2008-05-06),

13. 7285564 - Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds (2007-10-23),

14. 7060712 - [object Object] (2006-06-13),

Title: Ioanna Stergiades: Innovator in Mu Opioid Receptor Antagonists

Introduction

Ioanna Stergiades is a prominent inventor based in San Francisco, CA, known for her significant contributions to the field of pharmacology. With a total of 14 patents to her name, she has made remarkable advancements in the development of novel compounds that target the mu opioid receptor.

Latest Patents

One of her latest patents involves the invention of 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists. This invention provides novel compounds of formula (I), wherein R, R, R, A, and G are defined in the specification. These compounds are recognized as antagonists at the mu opioid receptor. Additionally, the invention includes pharmaceutical compositions comprising such compounds, methods for using them to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing these compounds.

Career Highlights

Ioanna has worked with notable companies such as Theravance, Inc. and Theravance Biopharma R&D IP, LLC. Her work in these organizations has contributed to her expertise and innovation in the pharmaceutical industry.

Collaborations

Some of her coworkers include Daniel D Long and John R Jacobsen, who have collaborated with her on various projects throughout her career.

Conclusion

Ioanna Stergiades stands out as a leading inventor in the field of mu opioid receptor antagonists, with a strong portfolio of patents and a successful career in pharmaceutical research. Her contributions continue to impact the development of new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.